anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Quote

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 18,554
Current window 15,451-15,480
Pages 619
Rows per page 30
Component: Quoteclear collectionreset all
18 30 60

Component

15,451-15,480 of 18,554

filter-aware
77
The slide serves as a negative testimonial/expert critique of the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
78
The slide uses direct quotes to highlight a lack of industry awareness and clinical skepticism regarding the drug's mechanism and efficacy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
79
The slide uses direct quotes to highlight the expert's negative sentiment and lack of awareness/enthusiasm for the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
80
The slide highlights the risk of off-label substitution for the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
81
The slide captures qualitative feedback from a medical expert, highlighting low adoption rates and negative sentiment toward the company's sales approach.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
82
The slide uses direct quotes to undermine the company's marketing claims and highlight physician concerns regarding side effects like diabetes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
83
The slide uses direct quotes from an expert to undermine the company's clinical narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
84
The slide uses direct quotes to undermine the company's marketing claims about drug efficacy and differentiation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
85
The slide uses direct quotes to highlight the physician's lack of confidence in the drug and his perception of external pressure from patient advocacy groups.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
86
The slide uses direct quotes to undermine the credibility of the drug's clinical narrative and the company's influence on investigators.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
87
The slide uses direct quotes to validate the activist's thesis regarding the drug's risks and market limitations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
88
The slide highlights the gap between physician prescribing behavior (driven by patient pressure) and their actual clinical belief in the product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
89
This slide presents qualitative interview data from a medical expert to undermine the credibility of a drug and a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
90
The slide uses direct quotes to frame the expert's skepticism regarding the company's marketing and clinical rationale.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
91
The slide uses direct quotes to highlight expert skepticism regarding safety, efficacy, and pricing.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
92
The slide presents qualitative expert feedback from a medical professional regarding drug safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
93
The slide presents qualitative feedback from a medical expert, highlighting concerns about diabetes risk and comparing the drug to the Aduhelm controversy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
94
This slide presents qualitative feedback from a medical expert, highlighting significant barriers to adoption for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
95
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
96
The slide presents a qualitative critique from a medical professional, highlighting skepticism regarding clinical efficacy and administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
97
The slide uses direct quotes to undermine the clinical value and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
99
The slide uses direct quotes to highlight the expert's negative sentiment and concerns regarding side effects and reimbursement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
100
The slide uses a direct quote to undermine the value proposition of the drug Vykat by highlighting the availability of cheaper alternatives.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
101
The slide uses direct quotes to expose contradictions in the drug's adoption and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
102
The slide uses direct quotes to support the thesis that generic substitution is likely and that GLP-1s are effective.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
106
The red box in the image highlights the specific rows in the table that the author claims are being used to obfuscate the diabetes signal.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
107
The slide uses red boxes to draw attention to the specific data points being compared.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
108
The slide uses a screenshot of an FDA Medication Guide to contrast with the claim that DKA is missing from clinical literature.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
111
The slide uses a combination of narrative summary and a Q&A transcript excerpt to build a case against the company's clinical trial transparency.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
113
The slide is a reproduction of a scientific poster (Gevers et al., 2024) used as evidence for clinical trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit